Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Becton looks to enter oncology screening market:

This article was originally published in Clinica

Executive Summary

Becton Dickinson has signaled its intention to move into oncology screening, staging and pharmacogenomics in a five-year strategic alliance with Millennium Predictive Medicine, a subsidiary of Millennium Pharmaceuticals. Becton Dickinson will pay $15 million upfront and a $3 million licensing fee, with overall investment totalling $70 million. At the same time Becton has also purchased a small privately-owned company which has interests in cancer diagnosis and management. Biometric Imaging has an FDA-approved diagnostic device and four tests, including cancer patient monitoring.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel